Filing Flows › Revvity (RVTY) › Q3 2026 › vs Q3 2025
Revvity (RVTY) Q3 2026 vs Q3 2025 (year over year)
Revvity's revenue rose $29.9M (+4%) from $699M in Q3 2025 to $729M in Q3 2026. The biggest changes: Life Sciences +$36.8M (+11%); Diagnostics −$6.8M (-2%). Operating margin 10.6% against 11.7% (-1.1 pts).
Revvity, Q3 2026: revenue $729M (+4% year over year), operating margin 10.6%, net earnings $62.3M, operating cash flow $167M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 10.6% | 11.7% | -1.1 pts |
| Net margin | 8.5% | 6.7% | +1.9 pts |
| Free cash flow margin | 20.9% | 17.2% | +3.7 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Life Sciences | $380M | $343M | $36.8M | +11% |
| Diagnostics | $349M | $356M | −$6.8M | -2% |
| Revenue | $729M | $699M | $29.9M | +4% |
| Operating profit | $77.4M | $81.9M | −$4.5M | -6% |
| Costs & expenses | $652M | $617M | $34.5M | +6% |
| Pre-tax earnings | $77.4M | $55.1M | $22.2M | +40% |
| Cost of revenue | $310M | $324M | −$14.0M | -4% |
| Research & development | $48.1M | $50.8M | −$2.7M | -5% |
| SG&A | $275M | $242M | $33.4M | +14% |
| Net earnings | $62.3M | $46.7M | $15.6M | +34% |
| Income tax | $15.1M | $8.5M | $6.6M | +78% |
| Depreciation & amortization | $103M | $102M | $857K | +0.8% |
| Share-based compensation | $9.8M | $9.1M | $698K | +8% |
| Working capital & other | $8.3M | $19.3M | −$11.0M | -57% |
| Operating cash flow | $167M | $138M | $28.2M | +20% |
| Free cash flow (OCF − capex) | $152M | $120M | $32.4M | +27% |
| Capital expenditures | $14.3M | $18.5M | −$4.2M | -22% |
Questions
How much did Revvity's revenue grow year over year in Q3 2026?
Revvity's revenue rose $29.9M (+4%) from $699M in Q3 2025 to $729M in Q3 2026.
What drove Revvity's revenue change in Q3 2026?
Life Sciences +$36.8M (+11%); Diagnostics −$6.8M (-2%).